Drugs / PRCL-02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03062618 | Feb 2017 → Feb 2018 | psoriasis | PRCL Research Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03614078 | Sep 2018 → Apr 2019 | psoriasis | PRCL Research Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRCL-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03062618 ↗ |
| Route | Oral | “Oral tablet(s) administered with water” NCT03062618 ↗ |